| Similar Articles |
|---|
 |
AboutSafety
March 8, 2001 |
Consumer Update On Mobile Phones The following summarizes what is known and what remain unknown about whether low levels of radiofrequency energy from mobile phones can pose a hazard to health and what can be done to minimize any potential risk.   |
The Motley Fool
June 30, 2010
Brian Orelli |
When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
AskMen.com
Jacob Franek |
Do Cell Phones Cause Cancer? The cellular phone is fast becoming the single most important piece of personal electronics - but at what cost and do cell phones cause brain cancer? |
Science News
May 13, 2000 |
Cancer Net CancerNet is a huge compendium of information on cancer assembled by the National Cancer Institute.... |
The Motley Fool
May 28, 2010
Brian Orelli |
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. |
PC Magazine
May 30, 2007 |
Mobile TV Hyperbole Cellular providers, mobile device makers, and TV networks are trying to convince you that everyone is watching mobile and online video. |
The Motley Fool
August 31, 2005
Rich Smith |
It's Not a Tumor Cell phones cause cancer, right? A new study suggests otherwise. Cell phone industry investors, rejoice! |
The Motley Fool
June 28, 2007
Brian Orelli |
Onyx's Hard at Work Onyx's future depends on getting Nexevar approved for new indications. The liver cancer expansion is a nice start, and it should bring Onyx into the black. Investors, take note. |
Chemistry World
September 2, 2014
Phillip Broadwith |
Exelexis slashes workforce by 70% The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer. |
AskMen.com
Dave Golokhov |
Cell Phones And Cancer With so much money in the cell phone industry, it looks like straight answers regarding the risks will be hard to come by. |
The Motley Fool
December 30, 2009
Brian Orelli |
Pfizer Pflubs -- You Expected Otherwise? Bad news, but rather expected. |
HHMI Bulletin
Nov 2010 |
Fusion genes that drive solid tumors are a new target for cancer therapies The success of Gleevec and related drugs has inspired researchers to step up their hunt for the molecular defects underlying other cancers. |
Delicious Living
May 2007
Emily Courtney |
Taking Prenatal Multis Helps Ward Off Childhood Cancers, Study Shows Mothers-to-be who take a multivitamin with folic acid before and during pregnancy may be protecting their children from several types of cancer. |
The Motley Fool
May 21, 2007
Mike Havrilla |
Allos Aligned for Success With two drugs that both sport reasonable chances of positive clinical data and FDA approval, biotech investors should take a look at Allos -- before any potential good news rolls in. |
The Motley Fool
May 28, 2009
Brian Orelli |
Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
October 27, 2011
Jim Royal |
I Can't Quit You, Big Tobacco Big Tobacco is being hit by challenges across the spectrum -- lawsuits, declining smoking rates, and new packaging rules -- but some companies have been able to claim victories of a sort. |
Managed Care
June 2007
Thomas Morrow |
Dendritic Cell Vaccine Hits FDA Roadblock Questions about study design and analysis prompted the FDA to postpone action on Provenge, a treatment for advanced prostate cancer. |
The Motley Fool
February 24, 2004
David Nierengarten |
Cell Genesys Boosted Cell Genesys's shares jump a day late and a dollar higher. |
AskMen.com
Dave Golokhov |
Men And Skin Cancer Men are three times more likely to develop skin cancer than women. While that's not breaking news, scientists have struggled to figure out the reason why men are more susceptible, and there appears to be a breakthrough. |
The Motley Fool
June 2, 2009
Brian Orelli |
Pfizer: If You Can't Beat 'Em, Join 'Em Sutent fails. Again. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. |
The Motley Fool
September 8, 2011
Brian Orelli |
Delayed Data Coming Soon? EXELent! Exelixis should have data on cabozantinib early in the fourth quarter. |
Managed Care
March 2007
Martin Sipkoff |
Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails. |
The Motley Fool
August 28, 2006
Will Frankenhoff |
China Unicom's Fading Signal Hear that investors? It's the sound of China Unicom playing second fiddle to China Mobile. |
BusinessWeek
May 20, 2010
Bob Van Voris |
Big Tobacco's Many Days in Court Facing thousands of lawsuits in Florida, cigarette makers are crying foul. |
PC Magazine
April 19, 2006 |
Bits & Bites v25n08 How fast does your brain process information? This website will tell answer that question. |
BusinessWeek
April 30, 2007
Catherine Arnst |
Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced. |
The Motley Fool
June 2, 2011
Luke Timmerman |
Infinity Dares to Think Big Against Pancreatic Cancer, Prepares to Show Early Results This Weekend Infinity Pharmaceuticals' top execs sometimes get strange looks when they say they are developing a new drug for pancreatic cancer. Is this a smart use of the company's time and resources? |
BusinessWeek
July 8, 2010
Rob Waters |
A Health Warning for a Wireless Age Despite a lack of definitive evidence tying cell phones to cancer, San Francisco wants consumers to know the emission levels of handsets. |
Wall Street & Technology
December 12, 2007
Melanie Rodier |
Agito Networks Releases RoamAnywhere Mobility Router The new router is a platform for mobile convergence with which an enterprise can leverage its WiFi networks for in-building mobile voice and data services. |
Scientific American
May 2009
Christine Soares |
Cancer Clues from Embryonic Development Rethinking cancer by seeing tumors as a cellular pregnancy. |
The Motley Fool
April 3, 2009
Brian Orelli |
Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately. |
Pharmaceutical Executive
February 1, 2013
William Looney |
In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer. |
The Motley Fool
September 14, 2009
Brian Orelli |
More Tests for Drug for Cancer Patients The Vanilla trial might not have come up positive, but at least sanofi-aventis and Regeneron Pharmaceuticals will keep trying to show that aflibercept is capable of helping cancer patients live longer. |
Pharmaceutical Executive
June 9, 2014 |
Immunotherapies: The New Hope for Cancer Treatment The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey |
Chemistry World
June 9, 2011
Sarah Houlton |
Asbestos linked to ovarian cancer Women exposed to asbestos fibers through work were one-and-three-quarter times more likely to develop ovarian cancer |
The Motley Fool
April 9, 2008
Brian Orelli |
Russia Approves an Unproven Treatment Antigenics gains approval of Oncophage in Russia, making it the first pharmaceutical to gain approval of any cancer vaccine. |
Fast Company
July 1, 2007 |
Going on the Gold Standard What it takes for your company to join the cancer fight. |
The Motley Fool
April 28, 2009
Brian Orelli |
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. |
The Motley Fool
September 28, 2010
Brian Orelli |
Pfizer's Sutent Fails. Again! No surprise here. |
Science News
May 19, 2007 |
Science Safari: Cancer Risk -- Understanding the Puzzle This new Web site from the National Cancer Institute cuts through the hype to help you understand the plain and simple truth about cancer risk. |
AskMen.com
Jacob Franek |
Prostate Cancer Overview Everything you wanted to know and more about prostate cancer in this three-part prostate cancer guide. |
Salon.com
August 10, 2000
Tabitha M. Powledge |
Is your cellphone killing you? A neurologist who's dying of a brain tumor is suing to try to prove that his phone is responsible. |
The Motley Fool
June 23, 2009
Brian Orelli |
Wonder Drug! Maybe? Get the facts before jumping on this one. |
The Motley Fool
August 10, 2005
Stephen D. Simpson |
China Mobile Still on the Move Look past the China hype, and you'll see that this leading cellular company has a solid business. More intrepid investors may want to take a look. |
American Family Physician
February 15, 2005 |
Health Care After Cancer Treatment An informative patient hand-out on follow-up cancer care. |
The Motley Fool
June 17, 2010
Luke Timmerman |
Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials. |
Bio-IT World
October 2006
Kevin Davies |
Cracking the Cancer Genome Regardless of which technologies win out, or which centers win the lucrative sequencing contracts, the Cancer Genome Atlas has a sublime medical and scientific importance, underscored by the latest findings from Hopkins. |
